Zhiyi Biologics Completes Nearly RMB 100 Million Series B+ Financing to Accelerate LBP Pipeline Development

Recently, Guangzhou Zhiyi Biological completed a Series B+ financing round of nearly RMB 100 million,Completed by Qingkong Jinxin Capital, the proceeds from the financing will be primarily used to accelerate the development of the company’s new drug pipeline and the construction of its R&D platform.. This marks another round of financing recently completed by ZYBio, following its RMB 110 million Series B round.

ZYBio is a leading enterprise in China in the field of live biotherapeutics (LBPs) and next-generation probiotics, with establishedGuangdong Provincial Engineering Technology Research Center for Live Biotherapeutic Products and Guangzhou Innovation Leading Team. The Company possesses a comprehensive technical system encompassing microbial and pathogen spectra, isolation of novel functional strains and target identification, development of new live biotherapeutic products, and development of active ingredient-based drugs, as well as an industrialization platform spanning from discovery and preclinical stages to New Drug Application (NDA). On this platform,In November 2019, the original innovative new drug SK08 Live Bacterial Powder (Bacteroides fragilis) was approved for clinical trials and has entered Phase II clinical trials. SK08 is the first LBP to enter clinical trials in China., a novel microbial strain featuring original innovation and exerting significant industry influence.

Currently, SK08 is also undergoing Phase II clinical trials for IBS-D, led by renowned gastroenterology experts Professor Chen Minhu and Professor Xiao Yinglian from the First Affiliated Hospital of Sun Yat-sen University, with patient enrollment already underway at hospitals in Guangzhou, Beijing, Shanghai, Nanjing, Wuhan, and other cities. Correspondingly, the company’s second new drug candidate, SK10, indicated for chemotherapy-induced diarrhea (CID), is approaching its Investigational New Drug (IND) application stage, while a new pipeline asset designed for combination therapy with immune checkpoint inhibitors is also set to advance rapidly into clinical trials. Meanwhile, multiple candidates in the company’s pipeline are progressing quickly and in an orderly manner.

Dr. Wang Ye, CEO of ZYBioThe company stated that the rapid and continuous advancement of its new strains and pipeline reflects the team’s deepening understanding of live biotherapeutic products (LBPs) and their sustained R&D efforts. We are highly confident that we will become a co-leader in the international LBP field within the foreseeable future. We thank our existing shareholders for their continued investment in this round, which serves as a strong endorsement of our work.

Tsinghua Holdings Jinxin CapitalIt was stated that the live biotherapeutic products (LBPs) sector, in which ZYBio operates, represents a frontier of global innovation and strategic deployment in biotechnology. We closely monitor the progress of leading international teams in this field. Following our participation in ZYBio’s Series A financing, its exceptional management team rapidly and efficiently advanced the SK08 project to clinical trial approval and into the currently ongoing Phase II clinical trials, demonstrating their profound expertise and execution capabilities in LBPs. ZYBio has emerged as a domestic leader in this sector. We believe that ZYBio’s increasingly robust R&D pipeline will meet a broader range of clinical needs.

Qinghua Jinxin was established in 2013. Leveraging Tsinghua University’s advantages in industry, academia, and research, and adhering to the philosophy of “technology as the foundation, finance as the tool,” it has deeply cultivated strategic emerging industries and the financial capital market. It has become a significant force driving the synergistic development of industry-finance integration within Tsinghua’s industrial ecosystem, and is a specialized institution under Qingtong Asset Management Group (a subsidiary of Tsinghua Holdings) focusing on industrial investment and asset management. To date, the total scale of funds managed by Qinghua Jinxin Capital exceeds RMB 25 billion.

Qingkong Jinxin remains dedicated to long-term value investing and investments in the high-tech sector. The company seeks to invest in enterprises led by entrepreneurs who possess both strong personal integrity and a visionary perspective, focusing on long-term growth opportunities driven by technological innovation. Its investment areas include strategic emerging industries such as information technology, biotechnology, energy and environmental protection, integrated circuits, artificial intelligence, and intelligent manufacturing. It has led or assisted in completing major investments and mergers and acquisitions totaling nearly RMB 100 billion, including deals with Maxscend Microelectronics, Will Semiconductor, Changyang Technology, Spreadtrum Communications, RDA Microelectronics, H3C, Wison Energy, TuoJing Environment, OmniVision Technologies, ZYBio, Huaqin Technology, Bozhong Precision Industry, Haoda Electronics, Tianyancha, and Vulcan.